Login to Your Account

Clinic Roundup

Tuesday, May 10, 2011
Chelsea Therapeutics International Ltd., of Charlotte, N.C., said an independent data safety monitoring board recommended continuation of its ongoing Phase II trial of CH-4051 in rheumatoid arthritis and that it should initiate enrollment in the 3-mg dose group. Ten patients have completed treatment in the 0.3-mg and 1-mg dose cohorts, with no negative safety signals found by the DSMB. For the remainder of the trial, patients will be randomized to 0.3 mg, 1 mg or 3 mg of CH-4051 daily, 3 mg CH-4051 daily with folate supplement, or methotrexate weekly with folate supplement for 12 weeks.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription